Endo International plc’s supplied case record shows a mature chapter 11 docket with the original debtor filing in place, related adversary litigation opened early in the case, and later Operand affiliate petitions added in 2023, but this context pack does not provide a confirmed plan, sale order, financing order, or pending hearing milestone.
Endo commenced chapter 11 on August 16, 2022 in the Southern District of New York through its Chapter 11 Voluntary PetitionDkt. 1. The first-day record framed the case around a specialty pharmaceutical business with a prepetition capital structure that included secured notes, unsecured senior notes due across 2023, 2025, and 2028, and credit facilities, as reflected in the Bradley first-day declarationDkt. 38.
The docket context then shows litigation activity alongside the restructuring. Endo Ventures opened an adversary proceeding against Nevakar and related entities in August 2022 through an adversary complaint for declaratory, injunctive, contract, and tortious-interference reliefDkt. 1. In September 2022, the debtors also filed an adversary complaint for injunctive relief against Kentucky and other defendantsDkt. 1, indicating that contested litigation management was part of the chapter 11 path from the outset.
The supplied record later expands the debtor perimeter rather than showing a final exit transaction: Operand Pharmaceuticals Holdco II Limited and Operand Pharmaceuticals Holdco III Limited filed chapter 11 petitions on May 25, 2023, followed by Operand Pharmaceuticals III Limited and Operand Pharmaceuticals II Limited on May 31, 2023, through their respective , , , and . The available context therefore supports a posture of an extended, multi-debtor pharmaceutical restructuring record, but not a specific current plan path or near-term court calendar.
